🇺🇸 FDA
Patent

US 11078286

Monoclonal antibodies specific for fibroblast growth factor receptor 4 (FGFR4) and methods of their use

granted A61KA61K2039/505A61K2039/5156

Quick answer

US patent 11078286 (Monoclonal antibodies specific for fibroblast growth factor receptor 4 (FGFR4) and methods of their use) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Jul 29 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Aug 03 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 29 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
9
CPC classes
A61K, A61K2039/505, A61K2039/5156, A61K39/0011, A61K39/39558